<DOC>
	<DOCNO>NCT01905215</DOCNO>
	<brief_summary>The purpose first time human ( FTiH ) study evaluate safety , reactogenicity immunogenicity several formulation Respiratory Syncytial Virus ( RSV ) investigational vaccine healthy men .</brief_summary>
	<brief_title>Study Evaluate Safety , Reactogenicity Immunogenicity GlaxoSmithKline ( GSK ) Biologicals ' Investigational Respiratory Syncytial Virus ( RSV ) Vaccines</brief_title>
	<detailed_description>This protocol post update follow protocol amendment 3 amend respective exclusion criterion exclude subject clinically significant hematological/ biochemical abnormality per opinion investigator .</detailed_description>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol . Written inform consent obtain subject . A male , include , 18 44 year age time vaccination . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine within 30 day precede dose study vaccine , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . Planned administration/ administration vaccine foreseen study protocol within period start 30 day end 30 day vaccination , exception license influenza vaccine may administer ≥ 15 day vaccination . Previous vaccination RSV . Chronic administration immunosuppressant immunemodifying drug within 6 month prior vaccine dose . Inhaled topical steroid allow . Administration longacting immunemodifying drug time study period . Administration immunoglobulins and/or blood product within 3 month precede dose study vaccine plan administration study period . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . History current autoimmune disease . History reaction hypersensitivity likely exacerbate component vaccine . Hypersensitivity latex . Any clinically significant hematological ( hemoglobin level , white blood cell [ WBC ] , lymphocyte , neutrophil , eosinophil platelet count ) biochemical ( alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] creatinine ) abnormality per opinion investigator , base local laboratory normal range . Subjects hematological/ biochemical value normal range expect temporary may rescreened later date . Any acute chronic , clinically significant disease , determine physical examination laboratory screen test . Malignancies within previous 5 year ( exclude nonmelanoma skin cancer ) lymphoproliferative disorder . Current alcoholism and/or drug abuse . Acute disease and/or fever time Screening . Fever define temperature ≥ 37.5°C /99.5°F oral , axillary tympanic route , ≥ 38.0°C /100.4°F rectal route . The preferred route record temperature study oral . Subjects minor illness ( mild diarrhea ) without fever may enrol discretion investigator . Subjects acute disease and/ fever time Screening may screen later date . Planned move location prohibit participate trial study end . Any condition investigator judge may interfere study procedure ( e.g . draw blood ) finding ( e.g . immune response ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Respiratory Syncytial Virus</keyword>
	<keyword>Reactogenicity</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Safety</keyword>
</DOC>